Minerva Neurosciences, Inc.

NASDAQ:NERV

Biotechnology

Healthcare
$2.18 -6.49%

-$0.30 today

Market cap
$108.64M
Beta
-0.11
P/E (TTM)
-0.2
EPS (TTM)
-$8.46
52W Low $1.76High $12.46

Volume 0.28M

Average 0.21M

NERV Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Minerva Neurosciences, Inc.NASDAQ: NERV

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables turns negative

Q2 FY2026 accounts payables was -$693.74K, compared with $256.85K a year earlier. Trailing-twelve-month accounts payables was $423.37K. Over 3 fiscal years it compounded at +6.2% a year.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near -$693.74K or moves back toward the trailing-twelve-month quarterly average of $105.84K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$693.74K-147.4% QoQ
Last fiscal yearDec 2025
-$1.06M+436.3% YoY
LTMJun 2026
$423.37K— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-370.1%——
1 year+436.3%——
3-year CAGR+6.2%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.06M) USD
Year-over-year change
-436.3%

Accounts Payables vs competitors

How NERV compares with its peers on the latest reported figures

  • NERV's LTM Jun 2026 accounts payables of $423.37K is the 3rd largest of the 4 companies compared; the peer median is $540K.
  • Over three fiscal years its annual growth of +6.2% compares with a peer median of +36.9%.
NERV Competitors Peer median
Accounts Payables for NERV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$3.18M +16967.7%+36.9%—
RLYBRallybio CorporationLTM Mar 2026$540K +871.4%—62.9%
NERVMinerva Neurosciences, Inc.LTM Jun 2026$423.37K —+6.2%—
NRXSNeurAxis, Inc.LTM Mar 2026$229.72K -67.3%—5.4%
Peer median (excluding NERV) $540K+871.4%+36.9%34.2%

Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.91M)(32.11M)(30.01M)1.44M(293.42M)
Depreciation & Amortization101.79K8.51K30.98K22.47K5.44M
Deferred Income Tax(1.8M)0000
Stock-Based Compensation5.22M4.11M1.97M1.33M1.33B
Change in Working Capital259.34K(4.06M)4.94M(320.6K)(632.35K)
Accounts Receivables00000
Inventory00000
Accounts Payables857.6K(883.55K)835.65K(197.48K)(1.06M)
Other Working Capital(598.27K)(3.18M)4.1M(123.13K)426.67K
Other Non-Cash Items21.53M7.41M8.28M(22.02M)(14.55B)
Operating Cash Flow(24.6M)(24.65M)(14.78M)(19.55M)(13.51B)
Capital Expenditures0(16.33K)000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(16.33K)000
Debt Repayment00000
Common Stock Issued0020M074.45M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities60M(5)(396.29K)074.38B
Financing Cash Flow60M(5)19.6M074.45B
Effect of Forex Changes00000
Net Change in Cash35.4M(24.66M)4.82M(19.55M)60.94B
Free Cash Flow(24.6M)(24.66M)(14.78M)(19.55M)(13.51B)

Minerva Neurosciences, Inc.

NASDAQ:NERV

Intrinsic Alpha fair value

Locked

Current Price

$2.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.